← Eichor
Study identifier: NCT07187440 Synced from ClinicalTrials.gov · July 31, 2026
● Recruiting

A Study of Agalsidase Alfa Enyzme Replacement Therapy in Chinese Children and Adults With Fabry Disease

Condition: Fabry Disease  ·  Sponsor: Takeda

PhaseN/A
Planned participants200
Who can joinAll sexes, 7 Years to no upper limit
Healthy volunteersNo

About this study

Fabry Disease is a rare blood disorder that some people are born with. People with Fabry disease have low levels of an enzyme called alpha-galactosidase A. This enzyme helps to cut down fat-like substances. Without alpha-galactosidase A, large forms of these substances build up and clot in blood vessels. Over time, this can affect vital organs (especially the heart, kidneys, and brain) causing serious health problems with advancing age. Agalsidase alfa (Replagal®) is a human enzyme made in the laboratory and may provide higher levels of alpha-galactosidase A. Replagal® works the same way as natural alpha-galactosidase A does. The main aim of this study is to learn more about the treatment with Replagal® in Chinese children and adults with Fabry disease. The study aims to assess the heart and kidney function in people with Fabry disease who are routinely treated with Replagal®. Other aims are to learn about the change in heart and kidney function, impact on quality of life, how the treatment with Replagal® works for people with Fabry Disease, and how safe the treatment with Replagal® is in routine real-world settings. Participants will receive with Replagal® per the routine treatment settings in China. No study-specific visits to the clinical are scheduled.

This description comes directly from the study's public registry record.

Talk to the study team

Takeda Contact  ·  +1-877-825-3327  ·  medinfoUS@takeda.com

Always discuss trial participation with your own doctor first.

Locations (18)

The First Affiliated Hospital Of USTC (AnHui Provincial Hospital)Hefei, Anhui, ChinaNot Yet Recruiting
Peking University First HospitalBeijing, Beijing Municipality, ChinaNot Yet Recruiting
Peking University Third HospitalBeijing, Beijing Municipality, ChinaRecruiting
Peking Union Medical College HospitalBeijing, Beijing Municipality, ChinaRecruiting
Fuzhou University Provincial Affiliated HospitalFuzhou, Fujian, ChinaRecruiting
The Second Affiliated Hospital ZheJiang University School Of MedicineHangzhou, Guangdong, ChinaNot Yet Recruiting
ShanTou Central HospitalShantou, Guangdong, ChinaRecruiting
The University Of Hong Kong-ShenZhen HospitalShenzhen, Guangdong, ChinaNot Yet Recruiting
The Second Hospital of Hebei Medical UniversityShijiazhuang, Hebei, ChinaRecruiting
The Second Affiliated Hospital of Harbin Medical UniversityHarbin, Heilongjiang, ChinaNot Yet Recruiting
Affiliated Drum Tower Hospital, Medical School of Nanjing UniversityNanjing, Jiangsu, ChinaRecruiting
The First Affiliated Hospital With NanJing Medical University(JiangSu Province Hospital)Nanjing, Jiangsu, ChinaNot Yet Recruiting

+ 6 more locations — full list on the registry record.

Follow this study

Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.

We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07187440